STAT2 antibody (C-Term)

Catalog No. ABIN964699

Supplier Product No.: 200-301-b65

This Mouse Monoclonal antibody specifically detects STAT2 in WB, IHC and ELISA. It exhibits reactivity toward Human.

Quick Overview for STAT2 antibody (C-Term) (ABIN964699)

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This STAT2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Clone: 19G8-H2-H6

Product Details anti-STAT2 Antibody

Binding Specificity: C-Term

Supplier Product No.: 200-301-b65

Supplier: Rockland

Purpose: Stat2 Antibody

Cross-Reactivity (Details): This Protein-A purified antibody is directed against human STAT2 protein. A BLAST analysis was used to suggest cross-reactivity with STAT2 protein from human, rat (73 % ) and mouse (76 %), sources based on homology with the immunizing sequence.

Characteristics: Synonyms: mouse anti-STAT2 antibody, Stat 2, Signal transducer and activator of transcription 2, p113

Purification: Protein A purified

Sterility: Sterile filtered

Immunogen:

Immunogen: This monoclonal antibody was produced by repeated immunizations with a synthetic peptide corresponding to residues near the carboxy terminus of mouse STAT2 protein.

Immunogen Type: Conjugated Peptide

Isotype: IgG2a kappa

Application Details

Application Notes:

Immunohistochemistry Dilution: 1:2.5 μg/mL

Application Note: This Protein-A purified antibody has been tested for use in ELISA, immunohistochemistry, and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 113 kDa in size corresponding to STAT2 protein by western blotting in the appropriate cell lysate or extract.

Western Blot Dilution: 1:1000

ELISA Dilution: 1:5,000 - 1:10,000

Other: User Optimized

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: None

Preservative: 0.01 % (w/v) Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Expiry Date: 12 months

Target Details for STAT2

Target: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Alternative Name: Stat2

Background: Background: STAT2 is a member of the STAT family of transcription factors.  Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex.  This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription.  Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation.  IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment.  Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha.  Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer.  From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.

Gene ID: 6773, 4885615

UniProt: Q9WVL2

Pathways: JAK-STAT Signaling, Hepatitis C, CXCR4-mediated Signaling Events